The potential value of very intensive therapy with autologous bone marrow rescue in the treatment of malignant lymphomas.

Autologous bone marrow transplantation (ABMT) following intensive therapy regimes is being used increasingly in relapsed lymphomas. To date no randomised studies have been performed to ascertain the value of this form of therapy. We describe here our experience of ABMT in both Hodgkin's disease and Non-Hodgkin's Lymphoma and review the situations in which we believe future randomised studies should be based.